Novocure to Participate in the BIO 2017 CEO & Investor Conference
07 February 2017 - 11:00PM
Business Wire
Novocure (NASDAQ:NVCR) announced today that it will participate
in the BIO 2017 CEO & Investor Conference on Feb. 13, 2017, in
New York City. William Doyle, Novocure’s Executive Chairman, will
speak on behalf of the company and address questions from
analysts.
Mr. Doyle’s presentation will begin at 5 p.m. EST. The audio
replay and presentation materials will be available via
Novocure.com for at least 14 days following the presentation.
About Novocure
Novocure is a commercial-stage oncology company developing a
proprietary therapy called Tumor Treating Fields, or TTFields, for
the treatment of solid tumor cancers. Novocure’s commercialized
product, Optune, is approved for the treatment of adult patients
with glioblastoma. Novocure has ongoing or completed phase 2 pilot
trials investigating TTFields in non-small cell lung cancer,
pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York
City. Additionally, the company has offices in Germany, Switzerland
and Japan, and a research center in Israel. For additional
information about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on March 1, 2016, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170207005531/en/
NovocureMedia and Investors:Ashley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024